Devonian Health Group Valuation

Is DVHG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DVHG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DVHG.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DVHG.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DVHG.F?

Key metric: As DVHG.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DVHG.F. This is calculated by dividing DVHG.F's market cap by their current revenue.
What is DVHG.F's PS Ratio?
PS Ratio	2.2x
Sales	CA$9.75m
Market Cap	CA$21.49m

DVHG.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	-8.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does DVHG.F's PS Ratio compare to its peers?

The above table shows the PS ratio for DVHG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.4x
LYRA Lyra Therapeutics	8.5x	61.6%	US$12.4m
EVOK Evoke Pharma	0.8x	59.5%	US$6.5m
IGC IGC Pharma	24.5x	10.1%	US$29.0m
IRD Opus Genetics	4x	62.0%	US$33.1m
DVHG.F Devonian Health Group	2.2x	n/a	US$21.5m

Price-To-Sales vs Peers: DVHG.F is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does DVHG.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 Companies	Price / Sales	Estimated Growth	Market Cap
OGN Organon	0.6x	-0.06%	US$4.12b
PRGO Perrigo	0.9x	3.4%	US$3.93b
BHC Bausch Health Companies	0.3x	1.5%	US$2.99b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.59b

70 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: DVHG.F is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is DVHG.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DVHG.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DVHG.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

-3.2%

70.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.5%

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

-0.2%

-7.1%